The estimated Net Worth of Todd Bazemore is at least $2.27 million dollars as of 26 June 2024. Mr. Bazemore owns over 4,653 units of Kala Bio stock worth over $499,901 and over the last 7 years he sold KALA stock worth over $92,490. In addition, he makes $1,674,110 as Chief Operating Officer at Kala Bio.
Sign up
Mr. Bazemore KALA stock SEC Form 4 insiders trading
Todd has made over 11 trades of the Kala Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,653 units of KALA stock worth $22,102 on 26 June 2024.
The largest trade he's ever made was selling 12,544 units of Kala Bio stock on 26 October 2021 worth over $22,579. On average, Todd trades about 1,619 units every 63 days since 2017. As of 26 June 2024 he still owns at least 83,040 units of Kala Bio stock.
You can see the complete history of Mr. Bazemore stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Todd Bazemore biography
Todd M. Bazemore serves as Chief Operating Officer of the Company. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc., or Santhera, a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., or Dyax, a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax’s commercial department including sales, marketing, commercial analytics, market access and patient services. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc., or Sunovion (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Business Unit. He received his Bachelor of Science from the University of Massachusetts, Lowell.
What is the salary of Todd Bazemore?
As the Chief Operating Officer of Kala Bio, the total compensation of Todd Bazemore at Kala Bio is $1,674,110. There are 1 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.
How old is Todd Bazemore?
Todd Bazemore is 49, he's been the Chief Operating Officer of Kala Bio since 2017. There are 10 older and 7 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
What's Todd Bazemore's mailing address?
Todd's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Insiders trading at Kala Bio
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... et Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
What does Kala Bio do?
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
What does Kala Bio's logo look like?
Complete history of Mr. Bazemore stock trades at Pulmatrix Inc et Kala Bio
Kala Bio executives and stock owners
Kala Bio executives and other stock owners filed with the SEC include:
-
Mark Iwicki,
Chairman of the Board, President, Chief Executive Officer -
Todd Bazemore,
Chief Operating Officer -
Eric Trachtenberg,
Chief Compliance Officer, General Counsel, Secretary -
Kim Brazzell,
Chief Medical Officer -
Mark T. Iwicki,
Chairman & CEO -
Dr. Kim Brazzell Ph.D.,
Head of R&D and Chief Medical Officer -
Hongming Chen,
Chief Scientific Officer -
Todd Bazemore,
Pres & COO -
Andrew Koven,
Lead Independent Director -
Rajeev Shah,
Independent Director -
Gregory Perry,
Independent Director -
Robert Paull,
Independent Director -
Howard Rosen,
Independent Director -
Gregory Grunberg,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
Mary Reumuth,
Chief Financial Officer, Treasurer -
James Patnoe,
Sr. VP of Market Access, Commercial Operations & Pricing -
Vincent Kosewski,
Sr. VP of Manufacturing & Supply Chain Management -
Michele LaRussa,
Sr. VP of Regulatory Affairs & Quality Assurance -
Kathleen McCann Kline,
Sr. VP of Marketing -
Eric L. Trachtenberg,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jill S. Steier,
Exec. Director of Investor Relations & Corp. Communications -
Mary Reumuth CPA, CPA,
CFO & Treasurer -
Dr. Justin Hanes Ph.D.,
Founder & Chair of the Scientific Advisory Board -
Capital Partners Ii, Llcenr...,
-
Harbor Master Investors (Ca...,
10% owner -
Associates, L.L.C.Caxton Co...,
-
Paulina Hill,
Director -
Advisors Llc Orbi Med Capit...,
-
Capital Management, L.P.Ra ...,
-
Robert I Tepper,
Director -
Robert Langer,
Director -
Advisors Llc Orbi Med Capit...,
-
Michele La Russa,
Sr. VP, Regulatory and Quality -
C. Daniel Myers,
-
Marjan Farid,
-
Capital Management, L.P.Ra ...,
-
Romulus K Brazzell,
SEE REMARKS -
Mark S. Blumenkranz,
-
Darius Kharabi,
CHIEF BUSINESS OFFICER